Key result
Plasma biomarkers including CRP and natriuretic peptides show potential to improve cardiovascular risk assessment.
Why the study?
Traditional risk factors do not fully explain predisposition to cardiovascular disease and treatment responses, creating a need for new biomarkers for risk stratification.
Do candidate plasma biomarkers improve risk stratification for cardiovascular events in asymptomatic individuals and those with overt disease?
Do candidate plasma biomarkers improve risk stratification for cardiovascular events in asymptomatic individuals and those with overt disease?
Candidate plasma biomarkers such as C-reactive protein, inflammatory mediators, and natriuretic peptides show promise in improving cardiovascular risk stratification beyond traditional risk factors.
The early identification of susceptibility to adverse cardiovascular outcomes and risk stratification amongst asymptomatic individuals, as well as amongst those with overt disease continues to be one of the major priorities of clinically-orientated research in the field of atherothrombosis. Available data from epidemiological studies indicate that traditional risk factors do not fully explain the predisposition to cardiovascular disease, its dynamics in different population groups and treatment responses. The pressing need for the development and clinical implementation of new markers of atherothrombotic disease has fuelled rapidly expanding research into cardiac biomarkers. This review outlines the main principles of biomarker qualification that have entered clinical practice, as well as an overview of the development of targeted biomarkers across the cardiovascular "continuum". We discuss in detail the evidence from epidemiological and clinical studies advocating the potential clinical use of the most promising candidate plasma biomarkers (more specifically, C-reactive protein, coagulation and inflammatory mediators and natriuretic peptides). Such an application of biomarkers to aid clinical risk assessment would be important in our efforts to improve risk stratification of subjects at risk of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Dotsenko et al. (2008) conducted a review in Cardiovascular disease. Candidate plasma biomarkers (C-reactive protein, coagulation and inflammatory mediators, natriuretic peptides) was evaluated. Candidate plasma biomarkers, including C-reactive protein, inflammatory mediators, and natriuretic peptides, show potential for improving clinical risk assessment across the cardiovascular continuum.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: